Loading...
Loading...
NRXP| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 1.0K |
| Gross Profit | -1.0K |
| Operating Expense | 5,997.0K |
| Operating I/L | -5,998.0K |
| Other Income/Expense | -530.0K |
| Interest Income | 27.0K |
| Pretax | -6,528.0K |
| Income Tax Expense | -42.3K |
| Net Income/Loss | -6,528.0K |
NRX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company's product portfolio includes ZYESAMI, an investigational drug for COVID-19 related respiratory failure, and NRX-100 and NRX-101 oral therapeutics designed for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.
